title: Mesenchymal stem cells as vectors for lung cancer therapy.
abstract: Despite recent advances in treatment, lung cancer accounts for one third of all cancer-related deaths, underlining the need of development of new therapies. Mesenchymal stem cells (MSCs) possess the ability to specifically home into tumours and their metastases. This property of MSCs could be exploited for the delivery of various anti-tumour agents directly into tumours. However, MSCs are not simple delivery vehicles but cells with active physiological process. This review outlines various agents which can be delivered by MSCs with substantial emphasis on TRAIL (tumour necrosis factor-related apoptosis-inducing ligand).
authors.affiliation: Lungs for Living Research Centre, University College London, London, UK.
authors.forename: Krishna K
authors.initials: KK
authors.lastname: Kolluri
authors.forename: Geoff J
authors.initials: GJ
authors.lastname: Laurent
authors.forename: Sam M
authors.initials: SM
authors.lastname: Janes
mesh_terms: D000818:Animals; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000502:physiology*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000008:administration & dosage*
chemical_list: D053221:TNF-Related Apoptosis-Inducing Ligand